Neutral
Syndax Pharmaceuticals (SNDX) reported a narrowed Q1 2026 net loss of US$42.7 million on revenues of US$64.9 million, showing progress towards profita...
Syndax Pharmaceuticals (SNDX) reported a Q1 loss of $0.48 per share, which is better than FactSet's estimated loss of $0.61 per share. The company is ...
![[8-K] Syndax Pharmaceuticals Inc Reports Material Event](https://www.sec.gov/Archives/edgar/data/0001395937/000119312526197124/img199102934_0.jpg)
Bullish
Syndax Pharmaceuticals Inc. reported a significant increase in Q1 2026 revenue, reaching $64.9 million, a 224% year-over-year jump, primarily driven b...